Tony Rice: Non-Executive Chairman
Committee Membership
Nomination (Chairman), Remuneration.
Skills and Experience
Tony has extensive board level experience across a range of sectors, including aerospace, healthcare, telecommunications and retail in both UK and international markets.
Background
Tony joined the Board in May 2016 and was appointed Chairman in October 2016. He served as Chief Executive Officer at Cable & Wireless and Tunstall Holdings, and prior to that held various roles at BAE Systems including Managing Director of Commercial Aircraft and Group Managing Director of Business Development. He has also served as a Non-Executive Director at Punch Taverns, Spirit Pub Company, Cable & Wireless, Telewest Communications and Saab Technologies, and Chairman of Alexander Mann Solutions.
External Appointments
Tony is currently the Senior Independent Non-Executive Director and Chairman of the Remuneration Committee at Halma plc and Chair at Ultra Electronics Holdings plc.
Ian Page: Chief Executive Officer
Committee Membership
Disclosure (Chairman).
Skills and Experience
Ian has gained detailed knowledge and experience through various positions he has held within the pharmaceutical and veterinary arena. He has a solid understanding of business development both in the UK and globally. In particular he has extensive experience in M&A and in the successful delivery of strategic plans.
Background
Ian joined NVS, Dechra’s former services business, at its formation in 1989 and was an integral part of the management buyout in 1997, becoming its Managing Director in 1998. He joined the Board in 1997 and became Chief Executive Officer in 2001. Ian has played a key role in the development of the Group’s growth strategy.
External Appointments
None.
Paul Sandland: Chief Financial Officer
Committee Membership
Not applicable.
Skills and Experience
Paul qualified as a Chartered Certified Accountant in 2005. He spent five years post qualification at KPMG, during which time he was part of the team which advised the Group on its acquisition of VetXX in 2008.
Background
Between 2012 and 2013 Paul was Acting CFO prior to becoming the Group’s Dechra Veterinary Products EU Finance Director. He was the Group Financial Controller of Dechra and Finance Director of Dechra Laboratory Services and Dechra Specialist Laboratories between January 2010 and April 2015. Paul was appointed as Acting Chief Financial Officer on 3 April 2019 and was appointed as an Executive Director and permanent Chief Financial Officer of the Company on 30 October 2019.
External Appointments
None.
Tony Griffin: Managing Director, Dechra Veterinary Products EU
Committee Membership
Not applicable.
Skills and Experience
Tony has over 30 years’ experience in the animal health business and has substantial international experience as a result of living and working outside the UK since 1993. He gained broad experience of running an international animal health business with teams in different European countries as Chief Executive Officer of the AUV Group. Tony is the Board nominated Director responsible for health, safety and environmental matters.
Background
Tony was appointed Managing Director of DVP EU in May 2012 following the acquisition of Eurovet Animal Health BV from AUV Holding B.V. He joined the AUV Group in 1993 as Director of Exports, having previously worked at Norbrook Laboratories and Moy Park. Tony was promoted to Managing Director of Eurovet in 1996, becoming the Chief Executive Officer of the AUV Group in 2006.
External Appointments
None.
Ishbel Macpherson: Senior Independent Non-Executive Director
Committee Membership
Audit, Nomination, Remuneration (Chairman).
Skills and Experience
Ishbel has a broad range of PLC Board experience in a variety of roles, including Chairman, Audit Committee and Remuneration Committee Chairman. She has knowledge and understanding of City matters gained over 20 years’ experience as an investment banker, specialising in UK mid-market corporate finance.
Background
Ishbel joined the Group as a Non-Executive Director in February 2013. Prior to this she was Head of UK Emerging Companies Corporate Finance at Dresdner Kleinwort Benson from 1999 to 2005, having previously worked at Hoare Govett and Barclays de Zoete Wedd.
External Appointments
Ishbel is Non-Executive Director at Workspace Group PLC (appointed January 2019) and Lloyd’s Registrar Group Limited (appointed August 2018).
Julian Heslop: Non-Executive Director
Committee Membership
Audit (Chairman), Nomination, Remuneration.
Skills and Experience
Julian has considerable financial experience as a result of the senior finance roles he has held in the pharmaceutical, food, property and brewing sectors over the last 30 years.
Background
Julian joined the Board in January 2013. He served as Chief Financial Officer of GlaxoSmithKline PLC (GSK) between 2005 and 2011, having previously been appointed its Senior Vice President, Operations Controller between 2001 and 2005 and as Financial Controller of Glaxo Wellcome PLC between 1998 and 2000. Prior to this, Julian held senior finance roles at Grand Metropolitan PLC and Imperial Brewing and Leisure. He is a Fellow of the Institute of Chartered Accountants in England and Wales.
External Appointments
None.
Dr Lawson Macartney: Non-Executive Director
Committee Membership
Audit, Nomination and Remuneration.
Skills and Experience
Lawson is a veterinarian and, in addition to spending several years in veterinary practice, has held a range of senior roles in pharmaceutical R&D, sales and marketing over the past 30 years.
Background
Lawson joined the Board in December 2016. He served as Chief Executive Officer of Ambrx Inc. between 2013 and 2015, and prior to that led emerging business for Shire PLC. Lawson was with GSK from 1999 to 2011 in positions of increasing seniority. His final role at GSK was to lead the strategic marketing, outcomes and reimbursement, project management and portfolio teams. In addition to his veterinary degree, Lawson has a PhD in viral pathobiology and is a pathologist, holding Fellowship of the Royal College of Pathologists as well as Membership of the Royal College of Veterinary Surgeons.
External Appointments
Lawson has been the Chairman of Viking Therapeutics Inc. since 2015, as well as the Chairman of the Nomination and Corporate Governance and a member of the Audit Committees. He is also a strategic adviser to several investment and private equity groups in both Europe and USA.
Lisa Bright: Non-Executive Director
Committee Membership
Audit, Nomination and Remuneration.
Skills and Experience
Lisa has strategic and operational leadership experience in global market leading pharmaceutical and emerging biotech companies gained over her 30 year career in the industry.
Background
Lisa joined the Board in February 2019. She is currently President International, and previously Chief Commercial and Corporate Affairs Officer of Intercept Pharmaceuticals, Inc, a global biopharmaceutical company focused on the development and commercialisation of novel therapeutics. Prior to this, Lisa held various Vice President roles at Gilead Sciences, Inc and GlaxoSmithKline plc, in Regional General Management, Government Affairs, and sales and marketing.
External Appointments
Lisa is also a Non-Executive Director at Ascendis Pharma A/S.
Navigation